Edition:
United States

Jounce Therapeutics Announces Update On Strategic Collaboration With Celgene Corp


Tuesday, 23 Jul 2019 04:00pm EDT 

July 23 (Reuters) - Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS ANNOUNCES UPDATE ON STRATEGIC COLLABORATION WITH CELGENE CORPORATION.JOUNCE THERAPEUTICS INC - CELGENE LICENSES JTX-8064, RESULTING IN $50.0 MILLION UPFRONT PAYMENT TO JOUNCE.JOUNCE THERAPEUTICS INC - JOUNCE RETAINS FULL WORLDWIDE RIGHTS TO VOPRATELIMAB, JTX‑4014 AND ALL DISCOVERY PROGRAMS.JOUNCE THERAPEUTICS INC - JOUNCE RETAINS FULL WORLDWIDE RIGHTS TO VOPRATELIMAB, JTX‑4014 AND ALL DISCOVERY PROGRAMS.JOUNCE THERAPEUTICS INC - UNDER TERMS OF NEW LICENSE AGREEMENT FOR JTX-8064, JOUNCE RECEIVES A $50.0 MILLION NON-REFUNDABLE LICENSE FEE.JOUNCE THERAPEUTICS INC - CELGENE WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION OF JTX-8064..JOUNCE THERAPEUTICS INC - REMAINS ON TRACK TO IDENTIFY RECOMMENDED PHASE 2 DOSE OF JTX-4014 IN 2019..JOUNCE THERAPEUTICS INC - ELIGIBLE TO GET FROM CELGENE UP TO $480 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.JOUNCE THERAPEUTICS INC - JOUNCE EXPECTS TO REPORT PRELIMINARY EFFICACY DATA AND BIOMARKER RELATIONSHIPS TO CLINICAL OUTCOMES FROM EMERGE IN 2020.JOUNCE THERAPEUTICS INC - JOUNCE NOW EXPECTS TO RECORD APPROXIMATELY $50.0 MILLION IN CASH REVENUE IN 2019 RELATED TO LICENSE OF JTX-8064.JOUNCE - CONTINUES TO EXPECT GROSS CASH BURN ON OPERATING EXPENSES, CAPITAL EXPENDITURES FOR FY TO BE ABOUT $80.0 MILLION TO $95.0 MILLION.